OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis

Area of Science:

• Oncology
• Pharmacology
• Nanotechnology

Background:

• Comprehensive anti-cancer strategies are needed to target proliferation, angiogenesis, and chemotherapy resistance.
• Existing treatments often face challenges with drug resistance and limited efficacy against multiple cancer hallmarks.

Purpose of the Study:

• To identify and evaluate a novel small molecule, OT-404, for its potential in cancer management.
• To assess OT-404's efficacy in inhibiting cancer cell proliferation and angiogenesis.
• To determine if OT-404 can overcome chemotherapy resistance and enhance treatment sensitivity.

Main Methods:

• In vitro studies on chemo-sensitive and chemo-resistant human cancer cell lines.
• In vivo evaluation of OT-404 efficacy in human tumor xenografts in nude mice.
• Assessment of OT-404, alone and encapsulated in nanoparticles, in combination with doxorubicin.

Main Results:

• OT-404 demonstrated significant inhibition of proliferation and angiogenesis in various human cancer cells.
• The compound effectively enhanced cancer cell sensitivity to chemotherapy, including in resistant cell lines.
• In vivo studies showed OT-404 inhibited doxorubicin-resistant breast cancer xenograft growth by over 80% and 95% in combination therapy.

Conclusions:

• OT-404 shows potential as a therapeutic agent for comprehensive cancer management.
• The small molecule effectively targets key cancer hallmarks and overcomes drug resistance.
• Nanoparticle formulation of OT-404 enhances its anti-tumor efficacy, particularly in combination therapy.